BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Interviews » Page 3

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Meet the New York Scientist Using Stem Cells as a Treatment For MS

September 6, 2021 By Cade Hildreth (CEO) 7 Comments

treatment for ms | How Dr. Sadiq's Stem Cell Research Is Advancing Treatment of Multiple Sclerosis

Treatment for multiple sclerosis (MS) is an evolving area and one in which new therapeutic approaches are rapidly advancing. Led by Dr. Saud Sadiq, the Tisch MS Research Center of New York is pursuing a Phase II clinical trial exploring the use of stem cell technology for the treatment for MS. The announcement followed positive results from an FDA-approved Phase I stem cell trial for MS. [Read more…]

Filed Under: Interviews, MSCs, Neural Stem Cells, Stem Cells Tagged With: mMultiple sclerosis

Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19

April 14, 2021 By Cade Hildreth (CEO) 1 Comment

Dr. Robert Hariri Celularity

With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.

Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).

In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]

Filed Under: Cell Therapy, Coronavirus (COVID-19), Interviews

Nucleus Biologics, Enabling Reproducible Science with David Sheehan (CEO)

February 20, 2021 By Cade Hildreth (CEO) Leave a Comment

David Sheehan, CEO of Nucleus Biologics
David Sheehan, CEO of Nucleus Biologics

In this interview with David Sheehan (CEO), we explore how Nucleus Biologics is revolutionizing the cell culture market through a concept known as “Precision Cell Culture.” The focus of Nucleus Biologics is to deliver superior cell culture products by leveraging a transparent, consistent and proven supply chain that eliminates variability for its customers. In addition to its novel Physiologix™ product line, Nucleus Biologics provides the highest quality Australia and New Zealand origin fetal bovine serum (FBS) available in the market with a goal to enable better lifesaving science.

With an estimated $28 billion lost per year to irreproducible biology research, it is clear that the market is overdue for disruption and Nucleus Biologics appears to be the company positioned to do it.  In this interview, we explore Mr. Sheehan’s background, the disruptive nature of Nucleus Biologics, and his inspiring vision for the future. [Read more…]

Filed Under: Interviews Tagged With: interview, Nucleus Biologics

Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics

February 15, 2021 By Cade Hildreth (CEO) Leave a Comment

Cellular Dynamics | Interview with Kaz Hirao, CEO of Cellular Dynamics International (CDI)

Fujifilm Cellular Dynamics is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.

The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.

[Read more…]

Filed Under: Interviews, iPS Cells

Stemmatters, a Portuguese Integrated Therapeutics Developer and Cell Therapy CDMO

January 1, 2021 By Cade Hildreth (CEO) Leave a Comment

Stemmatters

Stemmatters is a Portuguese contract development and manufacturing (CDMO) organisation based in Barco, Guimarães. Originally a spin-off from University of Minho, it offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices.

In the interview below, we explore Stemmatters history, services, manufacturing facilities, and future goals. Enjoy! [Read more…]

Filed Under: Cell Therapy, Interviews Tagged With: CDMO, interview, Stemmatters

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 14
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.